Back to Search

International Partner Search

Research & Development Request

Spanish biotech company is looking for partners to apply for a fast track to innovation H2020 call with the aim to develop and manufacture a molecular in vitro diagnostics (IVD) kit.

Country of Origin: Spain
Reference Number: RDES20200512001
Publication Date: 18 May 2020


The Spanish biotech is expert in the development of tools for the early diagnosis of colon cancer based on minimally invasive approaches. They have a molecular signature based on some protein and micro RNA (miRNA) biomarkers and look for partners for a consortium to generate antibodies, to develop assays for miRNAs and to manufacture the kit. The project will be submitted to fast track to innovation H2020 programme.


The company with wide expertise in the diagnosis of cancer is currently developing different in vitro diagnosis test. The most advanced product in its pipeline is being validated in a large prospective clinical study. Next step is the commercialization of the diagnosis test. 

The test is based on the determination of molecular biomarkers (combination of miRNAs and proteins in a predictive algorithm) which have been already validated by conventional ELISA/CLIA (enzyme-linked immune sorbent assay / chemi-luminescent immuno assay) and qPCR (quantitative polymerase chain reaction) in clinical trials.

We are looking for partners to prepare a project proposal to submit to fast track to innovation (FTI) call under Horizon 2020 programme.

Partners sought shall have experience in one of the following tasks:
-Generation of antibodies for protein biomarkers,
-Development of assays to detect miRNAs,
-Manufacturing of raw reagents necessary to analysis miRNAs and proteins.

The deadline of the call is 9th of June 2020. The project will last 30-36 months.

Advantages and Innovations

In vitro diagnosis test (IVD) has a high value of diagnostic procedures for patient management. New markers should deliver actionable and medically relevant information, to guide decision-making and foster improved patient outcomes.

The innovative IVD based on the determination of molecular biomarkers (combining miRNAs and proteins in a predictive algorithm) has been already validated in a large clinical study.

Next steps to fully commercial the kit would involve key partners with complementary background, knowledge and skills in the production of the reagents to analyze miRNA and proteins and scale-up, in the establishment of new value-chains to produce the reagents at industrial scale and in the commercialization of the kit and distribution into markets.

Stage Of Development

Field tested/evaluated

Requested partner

The company is looking for industrial partners interested in join a research cooperation agreement  for a FTI proposal. Partners search must have expertise in on e of these areas: generation of antibodies and/or assays for miRNAs and/or manufacturing reagents.

Cooperation offer is closed for requests